암발생에서 신혈관생성(angiogenesis)의 의미와 Mechanism, 현재 clinical trial의 전략정리.
*현*
다운로드
장바구니
소개글
서울대학교 약학대학 석사과정인 학생입니다.수업시간때 발표하기위해 Tumor angiogenesis에 관련된 mechanism과 그를 막기위한 방법들을
3가지 aspect로 분류하여 PPT를 만들었습니다. 그림들과 animation이 첨부되어 있습니다.
목차
-Clinical trials in now a days-VEGF trap
-Competitive peptide
-Receptor tyrosine kinase inhibitor
-Lessons from clinical data
-Conclusion
본문내용
Competitive peptideFor VEGFR
Nat. insight review
VEGF trap
Also called as decoy-soluble receptors
One of the ways to block the VEGF-signaling pathway for prevent VEGF from binding to its normal receptor by VEGF trap
There are active clinical trials about VEGF-trap
With or without Chemotherapies.
(Now 53 clinical trials goes on)
Sanofi-Aventis and partner Regeneron Pharmaceuticals have presented top-line
data showing that colorectal cancer candidate Zaltrap has come through a late-
stage study successfully. (Phase 3, 1,226 patients)
We can hopely expect to meet VEGF-trap drug in a near future!
Pharma-times : 2011. 4. 27
*
Competitive peptide
Aplidin(Plitidepsin®)
A marine cyclic depsipeptide derived from the Mediterranean tunicate Aplidium albicans
Aplidin-induced oxidative stress leads to increased
levels of cell membrane phospholipid as well as DNA
oxidation
Aplidin has shown anti-angiogenic activity in several
preclinical models through inhibition of the expression of
several angiogenic genes, including the vascular endothelial
growth factor (VEGF) and its receptor
참고 자료
Lessons from phase III clinical trials on anti-VEGF therapy for cancer, Rakesh K JainNATURE CLINICAL PRACTICE ONCOLOGY, 2006
VEGF-targeted therapy: mechanisms of anti-tumour activity, Lee M. Ellis, Nature review cancer, 2008
Therapeutic area crossroads: anti-angiogenesis ,Ryan P. Million, Nature reviews drug discovery, 2008
Angiogenesis as a therapeutic target, Napoleone Ferrara, Nature insight review, 2005
Biomarkers of response and resistance to antiangiogenic therapy, Rakesh K. Jain, Nature reviews clinical oncology, 2009
Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors, William P. Tew, Clin Cancer Res, 2010
Vascular Endothelial Growth Factor Trap in Non-Small Cell Lung Cancer, Gregory J. Riely, Clin Cancer Res, 2007
VEGF-Trap: A VEGF blocker with potent antitumor effects, Jocelyn Holash, PNAS, 2002
Antiangiogenic activity of aplidine, a new agent of marine origin, G Taraboletti, British Journal of Cancer, 2004
VEGF inhibition and cytotoxic effect of aplidin
이 자료와 함께 구매한 자료
[자연과학]혈관신생 (Angiogenesis) 9페이지
Angiogenesis보고서 13페이지
Tie2 보고서 23페이지